

Introduction to HER2- BC and HER2 Mechanism

Citation	Address
Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. <i>J Clin Oncol</i> . 2005;23:4215-4224.	https://pubmed.ncbi.nlm.nih.gov/15961768/
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. <i>N Engl J Med</i> . 2012;366:520-529.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705195/
Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. <i>Trans Med Chir Soc Edinb</i> . 1896;15:153-179.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518378/
Cohen MH, Hirschfeld S, Flamm Honig S, et al. Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrozole, paclitaxel, bexarotene. <i>Oncologist</i> . 2001;6:4-11.	https://pubmed.ncbi.nlm.nih.gov/11161223
Fareston (toremifene citrate) [package insert]. Bedminster, NJ; Kyowa Kirin Inc; Revised May 5, 2017.	http://fareston.com/uploads/documents/fareston-pi.pdf
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. <i>Lancet Oncol</i> . 2015;16:25-35.	https://pubmed.ncbi.nlm.nih.gov/25524798/
Fulvestrant (faslodex) [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; Revised August 2020.	https://medicalinformation.astrazeneca-us.com/home/prescribing-information/faslodex-pi.html
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. <i>N Engl J Med</i> . 2016;375:1738-1748.	https://pubmed.ncbi.nlm.nih.gov/27717303/
Ibrance (palbociclib) [package insert]. New York, NY; Pfizer Inc; Revised September 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103Orig1s012lbl.pdf

Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. <i>J Clin Oncol</i> . 2017;35:2949-2959.	https://pubmed.ncbi.nlm.nih.gov/28580868/
Kisqali (ribociclib) [package insert]. East Hanover, New Jersey; Novartis Pharmaceuticals Corporation; Revised July 2020.	https://www.novartis.us/sites/www.novartis.us/files/kisqali.pdf
Lynce F, Shajahan-Haq AN, Swain SM. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. <i>Pharmacol Ther</i> . 2018;191:65-73.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533626/
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. <i>Nat Rev Cancer</i> . 2011;11:558-572.	https://pubmed.ncbi.nlm.nih.gov/21734724/
Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. <i>J Clin Oncol</i> . 2017;35:2875-2884.	https://pubmed.ncbi.nlm.nih.gov/28580882/
Verzenio (abemaciclib) [package insert]. Indianapolis, IN; Eli Lilly & Co; Revised March 2020.	http://pi.lilly.com/us/verzenio-uspi.pdf
What is Advanced, Metastatic and Stage 3 & 4 Breast Cancer? Advanced Breast Cancer Community. Accessed August 22, 2020.	http://www.advancedbreastcancercommunity.org/understanding-abc
Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. <i>Cancer Cell</i> . 2006;9:23-32.	https://pubmed.ncbi.nlm.nih.gov/16413469/

1st Line Treatment with CDK 4/6 Inhibitors

Citation	Address
<p>Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies. <i>Future Med Chem.</i> 2015;7:1511-1519.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558537/</p>
<p>Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. <i>N Engl J Med.</i> 2016;375:1925-1936.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27959613/</p>
<p>Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. <i>J Clin Oncol.</i> 2017;35:3638-3646.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28968163/</p>
<p>Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. <i>N Engl J Med.</i> 2016;375:1738-1748.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27717303/</p>
<p>Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. <i>Ann Oncol.</i> 2018;29:1541-1547.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/29718092/</p>
<p>Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>NPJ Breast Cancer.</i> 2019;5:5.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/</p>
<p>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 5.2020. Published July 15, 2020</p>	<p>https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</p>
<p>Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. <i>Annu Rev Med.</i> 2011;62:233-247.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656649/</p>
<p>O'Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Res Treat.</i> 2018;168:127-134.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847028/</p>

Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. <i>Breast Cancer Res Treat.</i> 2019;174:719-729.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438948/
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. <i>Lancet Oncol.</i> 2018;19:904-915.	https://pubmed.ncbi.nlm.nih.gov/29804902/

Ribociclib in Premenopausal 1st-Line Metastatic Breast Cancer

Citation	Address
Bidard FC, Callens C, Dalenc F. Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. <i>J Clin Oncol.</i> 2020;38(15 suppl):1010	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1010
Chandralapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial. <i>JAMA Oncol.</i> 2016;2:1310-1315.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063698/
Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. <i>J Clin Oncol.</i> 2016;34:2961-2968.	https://pubmed.ncbi.nlm.nih.gov/27269946/
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. <i>Ann Oncol.</i> 2018;29:1541-1547.	https://pubmed.ncbi.nlm.nih.gov/29718092/
Hurvitz SA, Im SA, Lu YS, et al. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. <i>J Clin Oncol.</i> 2019;37(18 suppl):LBA1008	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18_suppl.LBA1008

Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. <i>N Engl J Med.</i> 2019;381:307-316.	https://pubmed.ncbi.nlm.nih.gov/31166679/
Jeannot E, Darrigues L, Michel M, et al. A single droplet digital PCR for ESR1 activating mutations detection in plasma. <i>Oncogene.</i> 2020;39):2987-2995.	https://pubmed.ncbi.nlm.nih.gov/32042112/
Spoerke JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of <i>ESR1</i> mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. <i>Nat Commun.</i> 2016;7:11579.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869259/
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. <i>Lancet Oncol.</i> 2018;19:904-915.	https://pubmed.ncbi.nlm.nih.gov/29804902/

CDK4/6 Inhibitors Combined with Fulvestrant

Citation	Address
Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. <i>Ann Oncol.</i> 2018;29(suppl 8):viii708.	https://www.annalsofoncology.org/article/S0923-7534(19)50400-8/fulltext
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncol.</i> 2016;17:425-439.	https://pubmed.ncbi.nlm.nih.gov/26947331/
Jhaveri KL. No clear survival benefit for fulvestrant versus letrozole in combination with palbociclib for endocrine-sensitive metastatic breast cancer [news release]. <i>ASCO Daily News.</i> Published May 29, 2020.	https://dailynews.ascopubs.org/doi/10.1200/ADN.20.200189/full/

<p>Llombart-Cussac A, Perez-Garcia JM, Bellet M, et al. PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. <i>J Clin Oncol.</i> 2020;38(15 suppl):1007.</p>	<p>https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1007</p>
<p>Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. <i>N Engl J Med.</i> 2020;382:514-524.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31826360/</p>
<p>Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. <i>J Clin Oncol.</i> 2018;36:2465-2472.</p>	<p>https://ascopubs.org/doi/10.1200/JCO.2018.78.9909?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmedhttps://pubmed.ncbi.nlm.nih.gov/29860922/</p>
<p>Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. <i>J Clin Oncol.</i> 2017;35:2875-2884.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28580882/</p>
<p>Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. <i>JAMA Oncol.</i> 2019;6:116-124.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31563959/</p>
<p>Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. <i>N Engl J Med.</i> 2018;379:1926-1936.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30345905/</p>

Abemaciclib and CDK4/6 Inhibitors vs Chemotherapy

Citation	Address
Hamilton E, Cortes J, Dieras V. Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer. <i>Cancer Res.</i> 2019;79(4 Suppl):PD1-11.	https://cancerres.aacrjournals.org/content/79/4_Supplement/PD1-11
Martín M, Zielinski C, Ruíz-Borrego M, et al. Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of palbociclib (PAL) in combination with endocrine therapy (ET) versus capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). <i>Cancer Res.</i> 2020;80(4 suppl):GS2-07.	https://cancerres.aacrjournals.org/content/80/4_Supplement/GS2-07
NCT02028507. Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL).	https://clinicaltrials.gov/ct2/show/NCT02028507

Monitoring and Managing Toxicities associated with CDK 4/6 Inhibition

Citation	Address
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncol.</i> 2016;17:425-439.	https://pubmed.ncbi.nlm.nih.gov/26947331/
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. <i>N Engl J Med.</i> 2016;375:1925-1936.	https://pubmed.ncbi.nlm.nih.gov/27959613/
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. <i>N Engl J Med.</i> 2016;375:1738-1748.	https://pubmed.ncbi.nlm.nih.gov/27717303/

Ibrance (palbociclib) [package insert]. New York, NY; Pfizer Inc; Revised September 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103Orig1s012lbl.pdf
Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>NPJ Breast Cancer</i> . 2019;5:5.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/
Kisqali (ribociclib) [package insert]. East Hanover, New Jersey; Novartis Pharmaceuticals Corporation; Revised July 2020.	https://www.novartis.us/sites/www.novartis.us/files/kisqali.pdf
Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: Detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). <i>Oncologist</i> . 2016;21:1165-1175.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061543/
Verzenio (abemaciclib) [package insert]. Indianapolis, IN; Eli Lilly & Co; Revised March 2020.	http://pi.lilly.com/us/verzenio-uspi.pdf

Multidisciplinary Team Tools

Citation	Address
Agency for Healthcare Research and Quality. The SHARE Approach Essential Steps of Shared Decisionmaking: Quick Reference Guide. Published April 2014.	https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/shareddecisionmaking/tools/tool-1/share-tool1.pdf
Agency for Healthcare Research and Quality. The CAHPS Ambulatory Care Improvement Guide: Practical Strategies for Improving Patient Experience; Section 6: Strategies for Improving Patient Experience with Ambulatory Care. Updated July 2017.	https://www.ahrq.gov/sites/default/files/wysiwyg/cahps/quality-improvement/improvement-guide/6-strategies-for-improving/communication/cahps-strategy-section-6-i.pdf
Agency for Healthcare Research and Quality. The SHARE Approach: A Model for Shared Decision Making. Published April 2016.	https://www.ahrq.gov/sites/default/files/publications/files/share-approach_factsheet.pdf

<p>Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. <i>Cochrane Database Syst Rev.</i> 2017;4:CD001431.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/24470076/</p>
<p>Moore S and Brandt ML. Adherence to Oral Therapies for Cancer: Helping Your Patients Stay on Course Toolkit. <i>Oncology Nursing Society.</i>2010. Accessed August 23, 2020.</p>	<p>http://msho.org/aws/MSHO/asset_manager/get_file/44984</p>
<p>Mehta P, Haggstrom DA, Latini DM, et al. Cancer survivorship care: Summarizing the 6 tools for success. <i>Fed Pract.</i> 2011;28(Suppl 6):43S-49S.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429039/</p>
<p>Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. <i>CA Cancer J Clin.</i> 2016;66:271-289.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27253694/</p>
<p>Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. <i>CA Cancer J Clin.</i> 2019;69:363-385.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31184787/</p>